LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...
The U.S. Customs and Border Protection made a large drug recovery along the border. CBP officers recently working commercial ...
Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback